Skip to main content
Erschienen in: Journal of Hematopathology 3/2019

08.06.2019 | Case Report

Co-occurrence of CALR and MPL somatic mutations in an Indian patient with a Philadelphia-negative myeloproliferative neoplasm

verfasst von: Ketki Kelkar, Vijay Ramanan, Siddharth Anand, Shatakshi Ranade, Kunal Patil, Meenal Agarwal, Nikhil Phadke

Erschienen in: Journal of Hematopathology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of clonal disorders that are characterized by excessive proliferation of abnormal myeloid precursors and mature cells. Somatic driver mutations in the JAK2, CALR, and MPL genes serve as major diagnostic criteria in the classification of the MPNs, namely polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Although initially thought to be mutually exclusive, recent studies have reported the co-existence of JAK2, MPL, and CALR mutations. In this case report, we describe a case of a Philadelphia-negative myeloproliferative neoplasm harboring mutations in the CALR [NM_004343.3:c.1092_1143del52 (NP_004334.1:p.Leu367Thrfs)] and MPL [NM_005373.2:c.1543T>A (NP_005364.1:p.Try515Arg)] genes. Given the rarity of documented co-occurrence of driver mutations in these two genes and the concomitant paucity of data regarding management of patients harboring mutations in both these genes simultaneously, there are no clear guidelines for the treatment of patients with these mutation patterns and hence it is difficult to assess the true relevance of this genotype. The fact that both the MPL and CALR genes are a part of the JAK-STAT pathway could, however, assist in the clinical decision-making process.
Literatur
1.
Zurück zum Zitat Frawley T, O’Brien C, Conneally E et al (2018) Development of a targeted next-generation sequencing assay to detect diagnostically relevant mutations of JAK2, CALR, and MPL in myeloproliferative neoplasms. Genet Test Mol Biomarkers 22:98–103CrossRefPubMed Frawley T, O’Brien C, Conneally E et al (2018) Development of a targeted next-generation sequencing assay to detect diagnostically relevant mutations of JAK2, CALR, and MPL in myeloproliferative neoplasms. Genet Test Mol Biomarkers 22:98–103CrossRefPubMed
2.
Zurück zum Zitat McGaffin G, harper K, Stirling D et al (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Hematol 167:276–278CrossRef McGaffin G, harper K, Stirling D et al (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Hematol 167:276–278CrossRef
3.
Zurück zum Zitat Kang MG, Choi HW, Lee JH et al (2016) Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 7:57036–57049PubMedPubMedCentral Kang MG, Choi HW, Lee JH et al (2016) Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 7:57036–57049PubMedPubMedCentral
4.
Zurück zum Zitat Rashid M, Ahmed Z, Ahmed S et al (2016) Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythaemia. Indian J Hematol Blood Transfus 32:112–116CrossRefPubMedPubMedCentral Rashid M, Ahmed Z, Ahmed S et al (2016) Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythaemia. Indian J Hematol Blood Transfus 32:112–116CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Cleyrat C, Chabot-Richards DS, Lynch DT et al (2017) Leukemic transformation of post-essential thrombocythemia myelofibrosis: a unique case presenting with double MPL and CALR mutations. Blood 130:4215 Cleyrat C, Chabot-Richards DS, Lynch DT et al (2017) Leukemic transformation of post-essential thrombocythemia myelofibrosis: a unique case presenting with double MPL and CALR mutations. Blood 130:4215
6.
Zurück zum Zitat Jeromin S, Meggendorfer M, Fasan A et al (2017) Frequency of concurrent BCR-ABL1, JAK2, CALR and MPL mutations in a cohort of 5,545 cases with suspected MPN by a deep sequencing approach. EHA Learn Center 2017:181088 Jeromin S, Meggendorfer M, Fasan A et al (2017) Frequency of concurrent BCR-ABL1, JAK2, CALR and MPL mutations in a cohort of 5,545 cases with suspected MPN by a deep sequencing approach. EHA Learn Center 2017:181088
7.
Zurück zum Zitat Usseglio F, Beaufils N, Calleja A et al (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythaemia. J Mol Diagn 91:92–98CrossRef Usseglio F, Beaufils N, Calleja A et al (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythaemia. J Mol Diagn 91:92–98CrossRef
8.
Zurück zum Zitat Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97:2071–2080CrossRefPubMed Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97:2071–2080CrossRefPubMed
9.
Zurück zum Zitat De Roeck L, Michaux L, Debackere K et al (2018) Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology 23:785–792CrossRefPubMed De Roeck L, Michaux L, Debackere K et al (2018) Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology 23:785–792CrossRefPubMed
10.
Zurück zum Zitat Mansier O, Paz DL, Lanotto JC et al (2018) Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93:E84–E109CrossRefPubMed Mansier O, Paz DL, Lanotto JC et al (2018) Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93:E84–E109CrossRefPubMed
11.
Zurück zum Zitat Ramanan V, Kelkar K, Ranade S et al (2016) The clinical utility of a custom-developed targeted next-generation sequencing assay for detection of mutations associated with Philadelphia negative chronic myeloproliferative neoplasms: two case examples with CALR exon 9 mutations. Int J MolImmunoOncol 1:28–34 Ramanan V, Kelkar K, Ranade S et al (2016) The clinical utility of a custom-developed targeted next-generation sequencing assay for detection of mutations associated with Philadelphia negative chronic myeloproliferative neoplasms: two case examples with CALR exon 9 mutations. Int J MolImmunoOncol 1:28–34
13.
Zurück zum Zitat Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRefPubMedPubMedCentral Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89:E121–E124CrossRefPubMed Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89:E121–E124CrossRefPubMed
15.
Zurück zum Zitat Pietra D, Rumi E, Ferretti VV, Buduo CAD, Milanesi C, Cavalloni C, Sant’Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431–438CrossRefPubMed Pietra D, Rumi E, Ferretti VV, Buduo CAD, Milanesi C, Cavalloni C, Sant’Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431–438CrossRefPubMed
16.
Zurück zum Zitat Defour JP, Chachoua I, Pecquet C, Constantinescu SN (2016) Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia 30:1214–1216CrossRefPubMed Defour JP, Chachoua I, Pecquet C, Constantinescu SN (2016) Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia 30:1214–1216CrossRefPubMed
Metadaten
Titel
Co-occurrence of CALR and MPL somatic mutations in an Indian patient with a Philadelphia-negative myeloproliferative neoplasm
verfasst von
Ketki Kelkar
Vijay Ramanan
Siddharth Anand
Shatakshi Ranade
Kunal Patil
Meenal Agarwal
Nikhil Phadke
Publikationsdatum
08.06.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Hematopathology / Ausgabe 3/2019
Print ISSN: 1868-9256
Elektronische ISSN: 1865-5785
DOI
https://doi.org/10.1007/s12308-019-00359-7

Weitere Artikel der Ausgabe 3/2019

Journal of Hematopathology 3/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie